Department of Pharmaceutical Sciences
UAMS College of Pharmacy
Dr. Stolarz's research interest is primarily focused on the mechanisms of damage to the lymphatic system during cancer therapy and developing therapeutic strategies to reduce this damage. Read more>
NCI Study of COVID-19 in Cancer Patients
Please note a very important study from the National Cancer Institute: IRB #261223(NCICOVID) NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
The Cancer Clinical Trials and Regulatory Affairs staff worked overtime to open this trial in 13 days after it was announced. The study follows along after a cancer patient is diagnosed with COVID-19, so there is very little burden to the patient or the treatment team. Because of the complexity around handling COVID-19 biospecimens, we’re not participating in the blood collection at this time.
To participate, a patient must have cancer and 1) be on active treatment, 2) be in follow-up after stem cell transplant or CAR T-cell therapy or 3) be in treatment for graft versus host disease. They also must have tested positive for COVID-19 within the past 14 days. Please note that we are not enrolling prisoners on this study.
CRAs (rather than research nurses) will consent patients after they have been identified. For help with enrollment, please call 686-8274.
UAMS Part of International Effort to Build AI Platform for Cancer Research
UAMS has received a four-year grant of $894,074 and will have a key role in a major international effort using artificial intelligence (AI) to teach computers at local research centers how to recognize cancer. The grant is part of EuCanImage, a nearly $9 million cancer research project based at the University of Barcelona in Spain.
A UAMS team led by Fred Prior, Ph.D., professor and chair of the College of Medicine Department of Biomedical Informatics,(pictured above) will lead the United States portion of the effort along with colleagues at Emory University in Atlanta. Read more>